<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-BOC-17010799</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-03-06</date_registration>
      <primary_sponsor>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</primary_sponsor>
      <public_title>Pathophysiological study of bone marrow mesenchymal stem cells in patients with acute myeloid leukemia</public_title>
      <acronym />
      <scientific_title>Pathophysiological study of bone marrow mesenchymal stem cells in patients with acute myeloid leukemia</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-03-15</date_enrolment>
      <type_enrolment />
      <target_size>Treatment group   Control group:60;Treatment group Control group:60;Treatment group Control group:60;Treatment group Control group:60;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=17014</url>
      <study_type>Basic science</study_type>
      <study_design>Case-Control study</study_design>
      <phase>Other</phase>
      <hc_freetext>Acute myeloid leukemia</hc_freetext>
      <i_freetext>Treatment group   Control group:in vitro culture;Treatment group Control group:cytarabine;Treatment group Control group:Adriamycin;Treatment group Control group:Daunorubicin;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jingying Cheng</firstname>
        <middlename />
        <lastname />
        <address>288 Nanjing Road, Heping District, Tianjin</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13820167873</telephone>
        <email>384891483@qq.com</email>
        <affiliation>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Tianxiang Pang</firstname>
        <middlename />
        <lastname />
        <address>288 Nanjing Road, Heping District, Tianjin</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18630963859</telephone>
        <email>pang@ihcams.ac.cn</email>
        <affiliation>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Diagnosed of having an Acute Myeloid Leukemia;
2. No limit in gender and the patients aged 3 to 80 years;
3. Signed a patient authorization form to use and disclose personal health information (or informed consent; participants under 18 years or thoese loss language ability can be signed by their guardians). </inclusion_criteria>
      <agemin>3</agemin>
      <agemax>80</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Diagnosed of having an Chronic Myeloid Leukemia;
2. Participates in a concurrent interventional clinical trial (phase 1, 2 or 3 or a Compassionate Use or Early Access Program). </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Survival and proliferation in vitro;IL8 expression level;Efflux rate of chemotherapeutic agents;apoptosis rate;Expression levels of cell cycle and apoptosis related proteins;Adipogenic and osteogenic differentiation;Expression profile of IL8 related genes;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Chinese National Natural Science Foundation</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-03-16</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>